[1] Myers KJ,Dean NM.Sensible use of antisense:how to use oligonucleotides as research tools[J].Trends Phimacol Sci,2000,21:19-23.
[2] Poston RS,Tran KP,Mann M J,et al.Prevention of ischemically induced neointimal hyperplasia using ex vivo antisense oligodeoxynucleotide[J].J Heart Lung Transplant,1998,17:349-355.
[3] Hnatowich DJ.Changing focus:applying antisense to nuclear medicine imaging[J].Mol Med Today,1999,5:151.
[4] ManiS,Gu Y,Wadler S,et al.Antisense therapeutics in oncology:points to consider in their clinical evaluation[J].Antisense Nucleic Acid Drug Dev,1999,9:543-547.
[5] Asaoka K,Tadam,Sawamura Y,et al.Dependence of efficient adenviral gene delivery in malignant glioma cells on the expression levels of the coxsackievirus and adenovirus recepter[J].J Neursurg,2000,92:1002-1008.
[6] Malatynska E,Matheson GK,Goldenberg R,et al.Effects of treatment with GABA(A) receptor subunit antisense oligodeoxynucleotides on GABA-stimulated 36C1-infiux in the rat cerebral cortex[J].Neurochem Int,2000,36:45-54.
[7] Cooper SR,Taylor JK,Miraglia LJ,et al.Pharmacology of antisense oligonucleotide inhiibitors of protein expression[J].Pharmacol Ther,1999,82.427-435.
[8] Hogrefe RI.An antisense oligonucleotide primer[J].Antisense Nucleic Acid Drug Dev,1999,9:351-357.
[9] Gauchez AS,Du Moulinet D'Hardemare A,Lunardi J,et al.Potential use of radiolabeled antisense oligonucleotides in oncology[J].Anticancer Res,1999,19:4989-4997.
[10] Alt M,Eisenhardt S,Serwe M,et al.Comparative inhibitory potential of diffently modified antisense oligodeoxynucleotides on hepatitis C virus translation[J].Eur J Clin Invest.1999,29:868-876.
[11] Hnatowich DJ.Antisense and nuclear medicine[J].J Nucl Med,1999,40(4):693-703.
[12] Tavitian B.In vivo antisense imaging[J].Q J Nucl Med,2000,44:236-255.
[13] Dewanjee MK,Vargas R,Ghafouripour AK,et al.Kinetics of intracellular hybridization of c-myc mRNA oncogene with 111In labeled antisense deoxyoligonucleotide probes in leukemic cells[J].J Nucl Med,1994,34:224.
[14] Lu Xiao-ming,Alan J,Fischman,et al.Antisense DNA delivery in vivo:Liver targeting by receptor-mediated uptake[J].J Nucl Med,1994,35:269-275.
[15] Dewanjee M K,Ghafouripour AK,Kapadvanjwala M,et al.Radiolabeled antisense oligodeoxynucleotides:in vitro and in vivo applications[J].JClin Immunoassay,1993,16:276-289.
[16] HnatowichDJ,Winnard P,Virzi F,et al.Technetium-99m labeling of DN A oligonucleotides[J].J Nud Mecl,1995,36:2306-2314.
[17] Hnatowich DJ.Antisense imaging:Where are we now?[J].Cancer Biother Radiopharm,2000,15:447-457.